Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes ...

Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology” start-ups.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Regeneron Pharmaceuticals Inc.-Bond has a maturity date of 9/15/2050 and offers a coupon of 2.8000%. The payment of the coupon will take place 2,0 times per biannual on the 15.03.. At the ...

Once upon a time, streaming services started and ended with Netflix and Hulu. Now, there's a seemingly endless array of apps to choose from, which can be both a blessing and a curse. We're here to ...

Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Affiliate links for the products on this page are from partners that compensate us and terms apply to offers listed (see our advertiser disclosure with our list of partners for more details ...